01 1Cadila Pharmaceuticals
01 1OLMESARTAN MEDOXOMIL USP
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2016-05-20
Pay. Date : 2013-09-11
DMF Number : 22861
Submission : 2009-08-26
Status : Active
Type : II
20
Cadila Pharmaceuticals Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is OLMESARTAN MEDOXOMIL USP, with a corresponding US DMF Number 22861.
Remarkably, this DMF maintains an Active status since its submission on August 26, 2009, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of May 20, 2016, and payment made on September 11, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II
